Glykit-M 2 Tablet SR is a combination oral antidiabetic medication containing Glimepiride 2mg and Metformin 500mg, formulated to improve glycemic control in patients with type 2 diabetes mellitus. Glimepiride, a sulfonylurea class agent, stimulates pancreatic beta cells to increase insulin secretion, thereby reducing blood glucose levels. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral glucose uptake and utilization, contributing to improved insulin sensitivity. The sustained-release (SR) formulation ensures a gradual release of active ingredients, promoting stable plasma drug concentrations and reducing gastrointestinal side effects commonly associated with immediate-release formulations. Glykit-M 2 Tablet SR is indicated as an adjunct to diet and exercise to improve glycemic control in adults when monotherapy with either agent is inadequate. It is essential to monitor blood glucose levels regularly and adjust dosage based on therapeutic response and tolerability. Caution is advised in patients with renal or hepatic impairment, cardiovascular disease, or predisposition to lactic acidosis. Common adverse effects may include hypoglycemia, gastrointestinal disturbances, and weight gain. This combination therapy offers a complementary mechanism of action, enhancing efficacy while minimizing individual drug-related adverse effects, thereby optimizing diabetes management.